PHILADELPHIA--(BUSINESS WIRE)--Tolerance Bio, Inc., a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners and individual biotechnology investors..

。。

Tolerance Bio is developing an allogeneic, or “off the shelf,” thymus induced pluripotent stem cell (iPSC)-based cell therapy platform as well as pharmacological thymus therapies to address immune-mediated diseases caused by abnormalities in immune tolerance, including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies..

Tolerance Bio正在开发一种基于异基因或“现成”胸腺诱导多能干细胞（iPSC）的细胞治疗平台以及药理胸腺疗法，以解决由免疫耐受异常引起的免疫介导的疾病，包括癌症，自身免疫，移植排斥，感染，免疫缺陷和过敏。。

“Defeating immune diseases has been the lifelong quest of this exceptional team we have assembled, with patients and their families always front and center for us,” said Francisco Leon, M.D., Ph.D., Co-Founder and Chief Executive Officer of Tolerance Bio. “We intend to rapidly advance and validate our pioneering concepts in a rare disease and then assess proof-of-concept in multiple major indications, advancing these novel therapeutics to target immune disease at its core.”.

Tolerance Bio联合创始人兼首席执行官Francisco Leon博士说：“战胜免疫疾病一直是我们组建的这支杰出团队的终身追求，患者及其家人始终站在我们的前面和中心。”我们打算迅速推进和验证我们在罕见疾病中的开创性概念，然后评估多个主要适应症的概念证明，推进这些以免疫疾病为核心的新型疗法。”。

The thymus, an organ in the chest, plays a crucial role in training T lymphocytes (T cells) to defend against threats such as infections and cancers while preventing autoimmunity. The T cell repertoire is developed in the first two years of life, and the thymus then declines with age, increasing the risk of immune diseases and mortality.

胸腺是胸部的一个器官，在训练T淋巴细胞（T细胞）抵御感染和癌症等威胁同时预防自身免疫方面起着至关重要的作用。T细胞库是在生命的头两年发展起来的，然后胸腺随着年龄的增长而下降，增加了免疫疾病和死亡的风险。

Tolerance Bio’s technologies aim to delay and prevent thymic involution and restore thymic function if lost, ultimately addressing these immune diseases and potentially increasing longevity..

Tolerance Bio的技术旨在延缓和预防胸腺退化，并在失去胸腺功能时恢复胸腺功能，最终解决这些免疫疾病并可能延长寿命。。

The iPSC technologies were initially developed at the University of Colorado and the University of Florida by Holger Russ, Ph.D., Scientific Co-Founder and Associate Professor, Department of Pharmacology and Therapeutics, Diabetes Institute at the University of Florida. The technologies were advanced alongside a proven team of drug and cell therapy developers, including Dr.

iPSC技术最初由科罗拉多大学和佛罗里达大学的Holger Russ博士开发，Holger Russ博士是佛罗里达大学糖尿病研究所药理学和治疗学系的科学联合创始人和副教授。这些技术与包括Dr。

Francisco Leon, former Co-Founder and Chief Scientific Officer of Provention Bio (acquired by Sanofi in 2023) and former Co-Founder, Chief Executive Officer, and Chief Medical Officer of Celimmune (acquired by Amgen in 2017)..

弗朗西斯科·莱昂（Francisco Leon），普罗旺斯生物（Provention Bio）（2023年被赛诺菲收购）的前联合创始人兼首席科学官，以及Celimmune（2017年被安进收购）的前联合创始人、首席执行官和首席医官。。

“After pioneering the generation of bioengineered thymuses from iPSC in vitro and in vivo, I am very excited for the opportunity to advance this technology to benefit patients,” said Dr. Holger Russ. “I couldn’t have found a more experienced and dynamic team to partner with than the cell and drug therapy experts at Tolerance Bio.”.

霍尔格·鲁斯博士说：“在开创了iPSC在体外和体内产生生物工程胸腺的先河之后，我非常高兴有机会推进这项技术，使患者受益。我找不到比耐受生物的细胞和药物治疗专家更有经验和活力的团队。”。

The Tolerance Bio team includes cell therapy experts such as Yeh-Chuin Poh, Ph.D., Vice President of Technical Operations, formerly with Semma Therapeutics (acquired by Vertex Pharmaceuticals in 2019) and Beam Therapeutics. The team also features experienced drug developers such as Justin Vogel, Chief Financial Officer; Phil Ball, Ph.D., Senior Vice President of Business Development and Operations; and Paul Dunford, Vice President of Translational Science.

Tolerance Bio团队包括细胞治疗专家，如Yeh Chuin Poh博士，技术运营副总裁，曾与Semma Therapeutics（2019年被Vertex Pharmaceuticals收购）和Beam Therapeutics合作。该团队还拥有经验丰富的药物开发人员，如首席财务官贾斯汀·沃格尔；Phil Ball博士，业务开发和运营高级副总裁；。

All three formerly worked at Provention Bio and each bring more than 20 years of biopharma experience from leading pharmaceutical companies such as Allergan, Janssen and Roche..

这三人以前都曾在普罗旺斯生物公司工作，他们都拥有Allergan、Janssen和Roche等领先制药公司20多年的生物制药经验。。

“The mission of Columbus Venture Partners is to support world-class teams to enable transformational technologies to become products and help people in need,” said Damia Tormo, Managing Partner of Columbus Venture Partners. “With Tolerance Bio, we not only have the prospect of preventing and treating immune disease but also possibly extending longevity, a tremendously exciting opportunity.”.

“哥伦布风险投资合作伙伴的使命是支持世界级的团队，使转型技术成为产品，并帮助有需要的人，”哥伦布风险投资合作伙伴的管理合伙人达米亚·托莫（DamiaTormo）表示。“通过Tolerance Bio，我们不仅有预防和治疗免疫疾病的前景，而且有可能延长寿命，这是一个非常令人兴奋的机会。”。

Pablo Cironi, Ph.D., Director at Criteria Bio Ventures added, 'We are excited to support Tolerance Bio in their mission to manipulate immune tolerance via thymus-based therapies, potentially transforming the landscape of immune-mediated diseases. The exceptional team at Tolerance Bio, with deep expertise across both cell and drug therapies, is uniquely positioned to bring these groundbreaking treatments to patients.

Criteria Bio Ventures董事巴勃罗·西罗尼（PabloCironi）博士补充道，“我们很高兴支持Tolerance Bio通过基于胸腺的疗法操纵免疫耐受，这可能会改变免疫介导疾病的格局。Tolerance Bio的杰出团队在细胞和药物治疗方面拥有丰富的专业知识，能够为患者带来这些开创性的治疗方法。

Their combined experience from leading biopharmaceutical companies will be key in advancing these innovative therapies and addressing unmet medical needs in immune disease management.'.

他们来自领先生物制药公司的综合经验将是推进这些创新疗法和解决免疫疾病管理中未满足的医疗需求的关键。”。

About Tolerance Bio, Inc.

关于Tolerance Bio，Inc。

Tolerance Bio, Inc., is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases. The company is based in Philadelphia, PA. For more information, visit www.tolerancebio.com or follow us on LinkedIn.

Tolerance Bio，Inc.是一家生物制药公司，专注于通过胸腺操纵免疫耐受，以解决各种免疫介导的疾病。该公司总部位于宾夕法尼亚州费城。有关更多信息，请访问www.tolerancebio.com或在LinkedIn上关注我们。

About Columbus Venture Partners

关于Columbus Venture Partners

Columbus Venture Partners is a Spanish venture capital firm that brings a unique approach to investing in outstanding opportunities in all stages of (bio)pharmaceutical drug development and advanced biopharmaceutical manufacturing technologies. Columbus VP manages over $400 million between its four funds and has built an impressive track record of performance with successful divestments in Viralgen, Askbio, PTS, Sanifit, Recovid, among others.

Columbus Venture Partners是一家西班牙风险投资公司，它在（生物）药物开发和先进生物制药制造技术的所有阶段都提供了独特的投资机会。哥伦布副总裁管理着4亿多美元的四只基金，并在Viralgen、Askbio、PTS、Sanifit、Recovid等基金的成功撤资中取得了令人印象深刻的业绩记录。

Columbus' professional team combines strong scientific, medical and business expertise with extensive experience in the field of corporate biotechnology. For more information, please visit: www.columbusvp.com.

哥伦布的专业团队将强大的科学、医学和商业专业知识与企业生物技术领域的丰富经验相结合。有关更多信息，请访问：www.columbusvp.com。

About Criteria Bio Ventures

关于Criteria Bio Ventures

Criteria Bio Ventures is a leading life sciences venture fund investing in transformative companies to shape the future of healthcare. We partner with driven entrepreneurs and fellow investors to build innovative companies with the potential to transform patients’ lives. Criteria Bio Ventures invests in global biotech companies that provide disruptive therapeutic approaches centered on addressing unmet medical needs, with a primary focus on Europe.

Criteria Bio Ventures是一家领先的生命科学风险基金，投资于转型公司，以塑造医疗保健的未来。我们与有动力的企业家和投资者合作，建立有潜力改变患者生活的创新公司。Criteria Bio Ventures投资于全球生物技术公司，这些公司提供以解决未满足的医疗需求为中心的颠覆性治疗方法，主要关注欧洲。

Criteria Bio Ventures is part of Caixa Capital Risc and the Criteria Caixa group, Spain’s largest investment holding with over €28 billion assets under management. For more information, visit: https://www.criteriabioventures.com/.

Criteria Bio Ventures是Caixa Capital Risc和Criteria Caixa group的一部分，后者是西班牙最大的投资控股公司，管理资产超过280亿欧元。有关更多信息，请访问：https://www.criteriabioventures.com/.

About BioAdvance

BioAdvance

BioAdvance is an $80-million early-stage life sciences fund with a focus on the mid-Atlantic region, investing in companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed more than $73 million in funding to approximately 115 organizations developing more than 208 products in the diagnostics, therapeutic, medtech, research tools, and digital health sectors.

BioAdvance是一个8000万美元的早期生命科学基金，重点关注大西洋中部地区，投资于有潜力改善人类健康的公司。自2003年首次投资以来，BioAdvance已承诺向大约115家组织提供7300多万美元的资金，这些组织在诊断、治疗、医学技术、研究工具和数字健康领域开发了208多种产品。

BioAdvance portfolio companies have leveraged $4.2 billion in subsequent capital, including proceeds from acquisitions. Twelve products have received FDA approval. For more information, please visit www.bioadvance.com..

BioAdvance投资组合公司在后续资本中杠杆化了42亿美元，包括收购收益。12种产品已获得FDA批准。有关更多信息，请访问www.bioadvance.com。。

About Ben Franklin Technology Partners of Southeastern Pennsylvania

关于宾夕法尼亚州东南部的Ben Franklin Technology Partners

Ben Franklin Technology Partners of Southeastern Pennsylvania (“Ben Franklin”) is the Philadelphia region’s Partners with a Purpose. Nationally ranked among the most active seed and early-stage investors, Ben Franklin helps high-growth innovative enterprises plant and nurture their roots, creating both immediate connections and lasting economic growth.

。在全国范围内，本·富兰克林是最活跃的种子和早期投资者之一，他帮助高增长的创新企业植根和培根，创造直接联系和持久的经济增长。

The nonprofit has supported more than 2,000 companies to deliver an impact of more than $5 billion and 32,000 jobs in the Philadelphia region. Whether in tech, life sciences, manufacturing, or industries and breakthroughs yet discovered, Ben Franklin works to raise the community of innovation higher, to benefit present and future generations of Pennsylvanians.

该非营利组织支持了2000多家公司，在费城地区创造了超过50亿美元的影响和32000个就业岗位。无论是在科技、生命科学、制造业还是尚未发现的行业和突破领域，本·富兰克林都致力于提高创新社区的地位，造福于宾夕法尼亚州的今世后代。

Visit us at partnerswithapurpose.org, or follow us at @bftp_sep..

请访问partnerswithapurpose.org，或访问@bftp\u sep。。